{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+Regimen&page=2", "query": { "intervention": "Treatment Regimen", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+Regimen&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T11:08:26.315Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01941316", "title": "Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Carcinoma", "Non Small Cell Lung Carcinoma", "Irinotecan Sensitive Cancers" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cancer Research and Biostatistics Clinical Trials Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2013-11", "completion_date": "2019-07-01", "has_results": true, "last_update_posted_date": "2024-05-09", "last_synced_at": "2026-09-28T11:08:26.315Z", "location_count": 8, "location_summary": "Goodyear, Arizona • Lexington, Kentucky • Louisville, Kentucky + 5 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01941316" }, { "nct_id": "NCT00536484", "title": "Fesoterodine Flexible Dose Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Overactive Bladder" ], "interventions": [ { "name": "Fesoterodine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 896, "start_date": "2007-08", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2009-09-15", "last_synced_at": "2026-09-28T11:08:26.315Z", "location_count": 95, "location_summary": "Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 81 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Rancho Cordova", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00536484" }, { "nct_id": "NCT05878184", "title": "Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "SC291", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sana Biotechnology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 16, "start_date": "2023-05-02", "completion_date": "2038-11-04", "has_results": false, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-09-28T11:08:26.315Z", "location_count": 7, "location_summary": "Duarte, California • Palo Alto, California • Atlanta, Georgia + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05878184" }, { "nct_id": "NCT01556347", "title": "Multi-Drug Desensitization Protocol for Heart Transplant Candidates", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Transplantation" ], "interventions": [ { "name": "Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "67 Years", "sex": "ALL", "summary": "18 Years to 67 Years" }, "enrollment_count": 2, "start_date": "2012-07", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2018-06-15", "last_synced_at": "2026-09-28T11:08:26.315Z", "location_count": 1, "location_summary": "Spokane, Washington", "locations": [ { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01556347" }, { "nct_id": "NCT00002235", "title": "A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Nelfinavir mesylate", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 6, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-28T11:08:26.315Z", "location_count": 5, "location_summary": "Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Hampton", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002235" }, { "nct_id": "NCT07214987", "title": "PDT For Induction Therapy For Head And Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma", "Head and Neck Cancer Squamous Cell Carcinoma", "Head and Neck Cancer" ], "interventions": [ { "name": "Toripalimab-tpzi", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2026-03-09", "completion_date": "2029-09-01", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-09-28T11:08:26.315Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07214987" }, { "nct_id": "NCT06203821", "title": "Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "NP137", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aram Hezel", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2026-09-01", "completion_date": "2032-09-30", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-09-28T11:08:26.315Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06203821" }, { "nct_id": "NCT00290433", "title": "Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Ara-C", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Doxil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2003-09", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2020-09-23", "last_synced_at": "2026-09-28T11:08:26.315Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00290433" }, { "nct_id": "NCT06948838", "title": "Improving Hypertension Control in Safety-Net Settings: The Boston Hypertension Equity Alliance in Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hypertension", "Hypertension Complicated" ], "interventions": [ { "name": "RBPM", "type": "BEHAVIORAL" }, { "name": "MII", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Boston Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16895, "start_date": "2025-09-08", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-09-28T11:08:26.315Z", "location_count": 7, "location_summary": "Boston, Massachusetts • Quincy, Massachusetts • Roslindale, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06948838" }, { "nct_id": "NCT00076752", "title": "Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lupus Erythematosus, Systemic" ], "interventions": [ { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Rituxan (rituximab)", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "15 Years to 40 Years" }, "enrollment_count": 9, "start_date": "2004-01-30", "completion_date": "2013-10-15", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-09-28T11:08:26.315Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00076752" } ] }